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Abstract
Calcium, phosphate and magnesium are essential for human function and life. Each elec-
trolyte is readily found in the human diet, and homeostasis is tightly regulated by the 
intestine, kidney and bone as well as other critical hormones, receptors and transporters. 
Disturbance to this balance can result in symptomatic disease and life-threatening mani-
festations. Calcium and phosphate are particularly co-dependent with disruption to the 
balance of one often influencing the other. It is important that clinicians have a thorough 
understanding of the mechanisms underplaying the homeostasis of each electrolyte as 
they have implications for prevention and management of disease. This chapter aims 
to outline the importance of calcium, phosphate and magnesium; the regulation of each 
electrolyte and the consequences of imbalance.
Keywords: calcium, magnesium, phosphate, parathyroid hormone, fibroblast 
growth factor, vitamin D, hypercalcaemia, hypocalcaemia, hyperphosphataemia, 
hypophosphataemia, hypermagnesaemia, hypomagnesaemia
1. Introduction
Calcium, phosphate and magnesium are electrolytes essential to human function and life. The 
balance of each electrolyte is reliant on the interplay between the gastrointestinal tract, kidney 
and bone. Other hormones, receptors and transporters are also integral to calcium, phosphate 
and magnesium homeostasis, influencing the actions of the intestine, kidney and bone. This 
chapter will outline the importance of calcium, phosphate and magnesium, the mechanisms 
for regulation and the consequences of imbalance.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Calcium
2.1. The importance of calcium
The human body contains 1–2 kg of the divalent cation calcium. Greater than 99% of calcium 
is stored in bone, and this provides structure for the human skeleton. The remaining calcium is 
stored in the intracellular and extracellular space. Beyond its structural importance, calcium plays 
a role in functions including intracellular signalling, neuromuscular transmission, muscular func-
tion, endocrinological function, coagulation and intercellular adhesion [1].
Calcium homeostasis is maintained through a delicate relationship between organs, including 
the kidneys, intestine, parathyroid glands, and bone. This is mediated by hormones such as para-
thyroid hormone (PTH), vitamin D3 (cholecalciferol), calcitriol (1,25-dihydroxycholecalciferol), 
fibroblast growth factor 23 (FGF23) and klotho [2].
2.2. Dietary calcium
Calcium accumulation commences in the third trimester of pregnancy and increases during 
childhood, adolescence and into early adulthood, at which time calcium storage peaks. The net 
balance of calcium is determined by the difference between calcium intake and calcium loss.
Throughout childhood and early adulthood, a positive calcium balance is required for bone 
growth. In this age group, as little as 500 mg of dietary calcium intake results in a positive 
calcium balance and the efficiency of intestinal calcium absorption can accommodate for the 
amount of calcium intake [3]. Between 25 and 35 years of age, when bone growth is com-
plete, the net calcium balance should be neutral. With ageing, bone mass decreases due to net 
resorption of bone at a rate of less than 1–2% per year [4]. However, menopause leads to a 
negative balance because of difficulties with intestinal absorption attributed to by oestrogen 
deficiency [2]. Postmenopausal women require 1200 mg of dietary calcium to achieve a posi-
tive calcium balance [3, 5].
2.3. Physiology of calcium
Calcium exists in the human body stored as bone (calcium hydroxyapatite) and is other-
wise found in the extracellular or intracellular space. One percent of skeletal calcium can 
be exchanged freely with the extracellular space via the osteoblastic and osteoclastic actions 
of bone [1, 4]. Forty-eight percent of serum calcium is ionised, and this is its physiologically 
active state. Forty-six percent is bound to protein, and 7% forms a complex with phosphate, 
citrate, sulphate, bicarbonate or other anions [1, 2].
Measurement of the plasma calcium is a reflection of the calcium bound to proteins such as 
albumin and immunoglobulin. The normal range is 2.1–2.6 mmol/L (8.5–10.5 mg/dL) [2]. For 
every 1 g/dL reduction in the serum albumin, serum calcium decreases by 0.8 mg/dL. Similarly, 
a 1 g/dL reduction in serum globulin results in serum calcium decreasing by 0.12 mg/dL [1]. 
While these formulas exist to calculate a corrected calcium level, they have been found to have 
poor sensitivity and specificity in detecting true hypocalcaemia or hypercalcaemia. Ionised cal-
cium levels are felt to be a more accurate representation of the physiologically active level [2].
Fluid and Electrolyte Disorders88
In the context of acute metabolic alkalosis, hydrogen ions dissociate from albumin. This sub-
sequently allows albumin to bind more calcium, decreasing the circulating ionised calcium. 
Ionised calcium levels will fall by 0.12 mg/dL for each change in pH of 0.1 [1].
Extracellular calcium homeostasis is mediated by the gastrointestinal system, kidneys and bone.
2.3.1. Renal handling of calcium
Around 8–10 g of ionised calcium is filtered by the kidneys each day. Of this, around 100–
200 mg (2–3% of total filtered calcium) is excreted in the urine [1, 3, 4].
Around 60–70% of calcium is reabsorbed in the proximal convoluted tubule (PCT). This 
mainly occurs passively via a transepithelial electrochemical gradient established by the reab-
sorption of sodium and water. A small amount of calcium is reabsorbed by active calcium 
transport. The process of reabsorption is controlled by PTH and calcitonin [1].
There is no calcium reabsorption in the thin loop of Henle, but a further 20% of calcium is 
reabsorbed in the thick ascending loop of Henle (TALH). This is predominately mediated by 
paracellular transport, although some transcellular movement occurs. The apical Na-K-2Cl 
(NKCC2) transporter and the renal outer medullary potassium channel (ROMK) produce a 
lumen-positive transepithelial gradient for paracellular cation transport, which is caused by 
a back flux of potassium into the lumen [6, 7]. This consequently causes paracellular calcium 
reabsorption as demonstrated in Figure 1 [1, 8]. It also contributes to the reabsorption of other 
cations such as magnesium and sodium.
Figure 1. Calcium reabsorption at the thick ascending limb of the loop of Henle. The apical Na-K-2Cl transporter and 
the renal outer medullary potassium channel are responsible for creating a transepithelial gradient, which drives 
paracellular calcium transport [1]
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Figure 2. Calcium reabsorption at the distal convoluted tubule. The protein transient receptor potential vanilloid 5 
(TRPV5) carries calcium across the apical membrane. Intracellularly calcium binds to calbindin-D28k travelling to the 
basolateral membrane. The sodium-calcium exchanger (NCX1) and the plasma membrane calcium ATPase reabsorb 
calcium into the blood [1].
The calcium-sensing receptor (CaSR) on the basolateral membrane of the TALH is a G- 
protein-coupled receptor. It is made up of a large extracellular and cytoplasmic domain [2]. 
Downregulation of the CaSR increases calcium permeability, while activation impedes per-
meability. The CaSR inhibits the ROMK channel in the presence of hypercalcaemia, leading 
to a reduction in paracellular sodium, calcium and magnesium transport [2, 9]. The CaSR 
enables the ionised calcium level to control renal calcium homeostasis independent of PTH 
or calcitriol [4].
Claudin-16 and claudin-19 are proteins expressed on the TALH, which facilitate paracellular 
absorption of divalent cations, including calcium and magnesium [1]. Mutations in claudin-16 
are responsible for causing familial hypercalciuria and hypomagnesaemia. Cinacalcet, used 
for the treatment of secondary hyperparathyroidism in chronic kidney disease, increases 
claudin-14 mRNA, which subsequently stimulates CaSR activity and decreases paracellular 
calcium reabsorption [9, 10]. Additionally, PTH and calcitonin upregulate active calcium 
reabsorption at the TALH [1].
The distal convoluted tubule (DCT) and collecting duct (CD) are responsible for calcium regu-
lation. Around 5–10% of calcium reabsorption occurs through active transport in the DCT, 
and this mechanism is entirely transcellular [1, 4]. Firstly, calcium travels across the apical 
membrane by the protein transient receptor potential vanilloid 5 (TRPV5). During this trans-
port process, intracellular calcium is bound to calbindin-D28k and moves towards the baso-
lateral membrane. Finally, calcium reabsorption happens with the help of the sodium-calcium 
exchanger (NCX1) in conjunction with the plasma membrane calcium ATPase (PMCA1b). 
This process is represented in Figure 2 [1, 8].
It is unclear how calcium is transported in the CD; however, a small amount of calcium is 
thought to be reabsorbed here [2].
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Many mechanisms regulate TRPV5 and therefore renal calcium handling. Mice with absent 
TRPV5 are known to have hypercalciuria despite normal serum levels of calcium. Their 
ability to maintain healthy serum calcium levels is believed to be due to increased intestinal 
absorption mediated by TRPV6 [11]. Calcitriol increases all proteins responsible for transport. 
Similarly, PTH stimulates TRPV5 and NCX1 while indirectly encouraging calcium reabsorp-
tion through the upregulation of calcitriol synthesis. TRPV5, NCX1 and calbindin-D28k are 
promoted by oestrogen [2].
2.3.2. Gastrointestinal handling of calcium
Not all dietary calcium is absorbed as calcium binds with anions (including phosphate and oxa-
late) in the intestinal lumen to form insoluble salts. Daily intestinal calcium absorption remains 
relatively constant (200–400 mg per day) despite fluctuations in dietary calcium intake [4, 8].
Gastrointestinal calcium absorption occurs by both transcellular and paracellular mecha-
nisms. The duodenum is the primary site where calcium is absorbed although it also occurs 
throughout the rest of the small bowel and colon. Transcellular transport is initially mediated 
by the TRPV6 channel seen on the apical membrane of the duodenum and proximal jejunum 
[8]. Similar to transcellular absorption in the DCT, once calcium is intracellular, it binds to 
calbindin, which helps transport the calcium to the basolateral membrane. Here, it is absorbed 
by calcium ATPase in conjunction with the sodium-calcium exchanger. This is a saturable 
form of absorption upregulated by calcitriol [2].
In the presence of high luminal calcium concentrations, the passive paracellular pathway of 
absorption predominates and this is driven by the large concentration gradient between the 
lumen and cell. This process is nonsaturable. Calcium is bound to the calmodulin-actin-myosin I 
complex and travels to the basolateral membrane by microvesicular movement [1, 12]. Calcitriol 
increases calbindin levels and also indirectly influences this process by changing the intracel-
lular tight junction structure [1].
Renal calcium excretion prevents dietary calcium overload, while renal reabsorption and bone 
resorption compensate for lack of transcellular uptake in the context of low dietary calcium.
2.3.3. Bone handling of calcium
Bone acts as a reservoir of calcium stored as hydroxyapatite (Ca10(PO4)6(OH)2). Trabecular bone is 15–25% calcified, while cortical bone is 80–90% calcified. Bone acts as an endocri-
nological organ by offering a readily exchangeable calcium pool, which is used to maintain 
calcium homeostasis while also allowing bone modelling and remodelling [2].
At any moment, 15–20% of bone is remodelling, facilitated by osteoblasts and osteoclasts. 
Osteoblasts are formed for pluripotent mesenchymal stem cells. When activated they assist 
with osteoclastogenesis, bone matrix production and bone mineralisation [13]. Osteoclasts, 
derived from circulating myeloid cells, are responsible for bone resorption by disrupting bone 
matrix mineralisation [2, 13].
Many factors influence bone homeostasis. Receptor activator of NF-κB ligand (RANKL) promotes 
osteoclast production. Osteoprotegerin (OPG) is a soluble receptor, which binds to RANKL and, 
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in doing so, inhibits osteoclast formation. The balance between RANKL and OPG determines 
the production and function of osteoclasts. PTH activates a PTH receptor (PTH1R) found on 
osteoblasts. When stimulated, PTH1R upregulates signalling, which favours osteoclast differ-
entiation and bone resorption [13]. The sclerostin/Wnt/beta-catenin pathway also plays a role in 
controlling bone remodelling whereby sclerostin, which is found in osteocytes, inhibits the Wnt/
beta-catenin pathway that works to promote bone formation [2].
2.3.4. Parathyroid hormone and calcium homeostasis
PTH is a polypeptide secreted from stowed granules in the parathyroid gland. Subsequently, 
metabolisation occurs in the liver and kidney. PTH causes increased plasma calcium levels 
when hypocalcaemia is detected by CaSRs located on parathyroid cells. It does this by encour-
aging bone resorption, stimulating intestinal absorption of calcium, upregulating calcitriol 
production in the kidney (by helping 1-α-hydroxylase that converts vitamin D to calcitriol) 
and increasing renal calcium reabsorption [1, 2, 4, 8]. PTH is the most significant modulator 
of calcium reabsorption in the kidney.
PTH secretion is modified by PTH gene transcription, which is upregulated by hypocalcaemia, 
glucocorticoids and oestrogen. On a post-transcriptional level, PTH is released in reaction to 
hypocalcaemia, adrenergic agonists, dopamine and prostaglandins [1]. Hypercalcaemia stim-
ulates intracellular destruction of PTH. Calcitriol inhibits PTH gene transcription by binding 
to the vitamin D receptor element (VDRE) on the PTH gene [2].
2.3.5. Parathyroid hormone-related peptide and calcium homeostasis
The discovery of parathyroid hormone-related peptide (PTHrP) was made when investigat-
ing the association between malignancy and hypercalcaemia [14]. Many cells produce PTHrP, 
which has a similar function and structure to PTH and subsequently activates the same recep-
tor as PTH. It is essential endochondral bone formation, smooth muscle relaxation and cel-
lular proliferation and differentiation; however, it appears to have a limited role in calcium 
homeostasis in healthy adults [4, 15].
PTHrP is known to be released by both solid organ and haematological malignancies, par-
ticularly squamous cell carcinoma. It results in a paraneoplastic hypercalcaemia as it binds to 
the PTH/PTHrP receptor causing calcium resorption from bone and renal calcium reabsorp-
tion. PTHrP-mediated hypercalcaemia is a poor prognostic marker in an individual with a 
malignancy [16].
2.3.6. Cholecalciferol, calcitriol and calcium homeostasis
The fat-soluble steroid vitamin D3 (cholecalciferol) is found in the diet and synthesised from 
7-dehydrocholesterol under the influence of ultraviolet (UV) light. Subsequently, it undergoes 
hydroxylation by the hepatic enzyme 25-hydroxylase, resulting in 25-hydroxyvitamin D (cal-
cidiol). Calcidiol circulates bound to vitamin D-binding protein where tubular cells that release 
1-α-hydroxylase and 24-α-hydroxylase convert calcidiol to 1,25-dihydroxycholecalciferol 
(calcitriol) and 24,25-dihydroxycholecalciferol. 24,25-Dihydroxycholecalciferol is an inactive 
metabolite of vitamin D3 [1, 2, 8, 17]. This process is depicted in Figure 3.
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Calcitriol increases renal reabsorption of calcium and intestinal absorption of calcium and 
phosphate, increases the mineralisation of bone and reduces PTH synthesis.
2.3.7. Fibroblast growth factor 23, klotho and calcium homeostasis
Fibroblast growth factor 23 (FGF23) is comprised of 251 amino acids and is produced by 
osteocytes during bone remodelling. Klotho, expressed in the kidney, parathyroid gland, 
skeletal muscle and choroid plexus, is a coreceptor for FGF23. Klotho upregulates the affin-
ity of FGF23 to its receptors [18]. FGF23 production causes reduction in calcitriol levels as 
it blocks 1-α-hydroxylase in the kidney causing increased 24-hydroxylase, which, in turn, 
causes vitamin D degradation. Additionally, it inhibits PTH release. PTH and hypercalcaemia 
stimulate FGF23, whereas calcitriol and hypocalcaemia impede its production [19].
FGF23 and klotho also play an important role in phosphate homeostasis, which will be dis-
cussed later in the chapter.
2.4. Hypercalcaemia
Hypercalcaemia is a result of disrupted calcium homeostasis and can be caused by alterations 
to organs, hormones or transporters involved in calcium regulation.
Figure 3. Overview of the metabolism of calcitriol (1,25(OH)2D). Vitamin D3 (cholecalciferol) is synthesised from 7-dehydrocholesterol in the presence of UV light and is present in the diet (along with vitamin D2). It is hydroxylated by the hepatic enzyme 25-hydroxylase resulting in 25-hydroxyvitamin D (calcidiol). Calcidiol circulates bound to vitamin 
D binding protein. Tubular cells release 1-α-hydroxylase (CYP27B1) and 24-α-hydroxylase, which convert calcidiol to 
1,25-dihydroxycholecalciferol (calcitriol) and 24,25-dihydroxycholecalciferol.
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Increased intestinal absorption can be secondary to increased calcium intake, as seen in milk-
alkali syndrome, or calcium supplementation [20]. Elevated calcitriol can be seen in primary 
hyperparathyroidism, T cell lymphomas and vitamin D intoxication. Granulomatous diseases 
(sarcoidosis, tuberculosis) also cause a rise in calcitriol due to autonomous 1-α-hydroxylase 
activity in macrophages within granulomas. Increased levels of calcitriol stimulate intestinal 
absorption of calcium as well as renal calcium reabsorption. Hyperparathyroidism, increased 
PTHrP, bony metastases, myeloma, phosphate depletion, immobilisation and metabolic aci-
dosis lead to increased bone resorption, which may result in hypercalcaemia. Inability to pro-
duce bone, as seen in adynamic bone disease, can also lead to hypercalcaemia. Finally, high 
calcium levels can be a result of decreased renal excretion of calcium due to volume depletion, 
thiazide diuretic use or alkalosis [3].
Familial hypocalciuric hypercalcaemia is an autosomal dominant condition caused by a muta-
tion, resulting in loss of function in the CaSR gene. It creates hypocalciuria in the setting of hyper-
calcaemia, associated with hypophosphataemia, hyperchloraemia and hypermagnesaemia. 
Patients are mostly asymptomatic although severe hyperparathyroidism can occur in affected 
neonates [21].
2.4.1. Clinical manifestations of hypercalcaemia
Patients with hypercalcaemia can be asymptomatic at time of presentation or can present with 
any or all of the following: fatigue, mood changes, confusion, nausea, vomiting, loss of appetite, 
constipation, polyuria, and weakness. Symptoms are seen more often once calcium levels are 
greater than 2.9 mmol/L (11.6 mg/dL) or in the setting of acute changes to serum calcium levels. 
Hypercalcaemia can cause cardiac conduction defects including a short QT interval, which may 
potentiate a cardiac arrhythmia. Renal tubular damage and calcification involving the vascula-
ture, kidneys, skin, lungs, heart and stomach may follow, especially in the setting of normophos-
phataemia or hyperphosphataemia. Calcium levels above 3.7 mmol/L (14.8 mg/dL) can result in a 
comatose state or a cardiac arrest. Renal calculi are associated with chronic hypercalcaemia [4, 22].
2.4.2. Treatment of hypercalcaemia
It is essential to consider and treat the underlying aetiology when managing hypercalcaemia. 
Treatment approaches depend on the severity and symptomatology of the patient. For mild 
hypercalcaemia (few symptoms or calcium of <3 mmol/L (<12 mg/dL)), treatment with sup-
portive measures while addressing the underlying disease is appropriate. Intravenous fluids 
can be used to restore euvolaemia in order to reduce PCT calcium reabsorption and enhance 
calcium excretion. Avoiding calcium-containing medications and maintaining a low calcium 
diet is necessary for ongoing management [22].
In those with significant symptoms or calcium levels >3 mmol/L (>12 mg/L), more aggressive 
therapy is warranted. Intravenous fluids remain the first step in treatment, and the rate of 
administration is mainly governed by the degree of hypercalcaemia. Fluid administration is 
thought to lower serum calcium levels by 0.5 mmol/L (2 mg/dL). Loop diuretics can be used 
once the volume state is restored to prevent renal calcium reabsorption. However, with the 
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introduction of bisphosphonate therapy for the management of hypercalcaemia, loop diuret-
ics are less frequently utilised unless the patient is suffering from hypervolaemia, oliguric 
renal failure or congestive cardiac failure [22].
Calcitonin, produced by parafollicular C cells in the thyroid, is effective in lowering serum cal-
cium quickly in cases of severe hypercalcaemia. It acts by blocking osteoclasts and promoting 
calciuria. Unlike bisphosphonates and steroids, calcitonin works within 4–6 hours; however 
its effect only lasts for 48–72 hours, because of rapid development of tachyphylaxis, and there-
fore, it requires administration in conjunction with a longer-acting treatment strategy [22].
Bisphosphonates (particularly, intravenous pamidronate and zoledronate) are used for malig-
nancy-related hypercalcaemia as they inhibit osteoclast action and, therefore, bone resorption. 
They take 24–48 hours to work. Dose and infusion rate needs to be adjusted to the patient’s 
renal function [23], and risks of treatment include jaw osteonecrosis, uveitis and nephrotoxicity. 
Denosumab, an antibody against RANKL, has also been used for the treatment of hypercalcae-
mia of malignancy and has proven effective in bisphosphonate-resistant disease [24].
In calcitriol-mediated hypercalcaemia (e.g., sarcoidosis, tuberculosis), corticosteroids, in con-
junction with a low calcium diet, are adequate. Steroids work by inhibiting 1-α-hydroxylase 
so that calcidiol is unable to be converted to calcitriol.
In those with a parathyroid adenoma causing primary hyperparathyroidism and resultant 
hypercalcaemia, surgical removal of the adenoma is necessary.
Due to the availability of bisphosphonates, the need for dialysis in hypercalcaemia has been 
reduced, but it continues to play a role in individuals with oliguric acute kidney injury, life-
threatening manifestations of hypercalcaemia or states refractory to other treatment strategies [4].
2.5. Hypocalcaemia
As previously discussed, PTH is essential in maintaining calcium homeostasis, and in hypo-
parathyroidism (hereditary or acquired), the absence of PTH means that serum calcium levels 
are unable to be preserved. Severe hypomagnesaemia (<0.4 mmol/L or <0.8 meq/L) can cause 
hypocalcaemia as it paradoxically impairs PTH release and causes PTH resistance [4]. Dietary 
deficiency, anticonvulsant therapy, malabsorption, hepatobiliary disease, renal failure and lack 
of sunlight cause vitamin D deficiency, leading to hypocalcaemia. Drastic reductions in extracel-
lular calcium levels, seen in pancreatitis, severe acute hyperphosphataemia and rhabdomyolysis, 
lead to hypocalcaemia as PTH is unable to compensate quickly enough to maintain homeostasis.
2.5.1. Clinical manifestations of hypocalcaemia
The level of calcium and the rate of change will determine the manifestation of symptoms in 
hypocalcaemia. Common symptoms of hypocalcaemia include fatigue, weakness, irritability, 
confusion and mood changes. Pathognomonic signs of hypocalcaemia are Trousseau’s sign (car-
popedal spasm occurs when a blood pressure cuff inflated above the systolic blood pressure) 
and Chvostek’s sign (facial muscle spasm following tapping over the facial nerve) [25]. These 
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signs occur due to neuromuscular excitability [26]. Individuals can also complain of lip paraes-
thesia, cramping and may experience laryngospasm, bronchospasm, frank tetany or seizures. 
Cardiac arrhythmias can also occur as low calcium can cause a prolonged QT interval. Chronic 
hypocalcaemia is associated with cataracts, brittle nails, dry skin and reduced body hair [21].
2.5.2. Treatment of hypocalcaemia
Hypocalcaemia is potentially life-threatening, and any individual experiencing laryngospasm, 
bronchospasm or seizures should be treated immediately with intravenous calcium. Calcium 
gluconate can be given peripherally as it causes less local irritation than calcium chloride, 
which requires administration by central venous access [27]. Patients receiving intravenous 
calcium should be cardiac monitored as rapid correction can also precipitate arrhythmias [26]. 
Hypomagnesaemia associated with hypocalcaemia requires treatment with intravenous mag-
nesium initially, followed by calcium correction. Less acute presentations of hypocalcaemia 
can be treated with oral calcium supplementation (e.g., calcitriol). The daily replacement dose 
can be between 2 and 4 g of elemental calcium.
Treatment of the underlying cause of hypocalcaemia is essential. In cases of hypocalcaemia 
due to hypoparathyroidism, treatment with calcium leads to increased calciuresis, which may 
result in nephrocalcinosis and renal impairment. To reduce calciuresis, thiazide diuretics can 
be used in association with reduced salt and increased fluid intake. Regular monitoring of 
serum calcium levels is required.
3. Phosphate
3.1. The importance of phosphate
Phosphate plays a role in skeletal integrity, skeletal development, cell structure, cellular 
signalling, protein synthesis and energy metabolism [28]. Eighty-five percent of biological 
phosphorus is stored in the bone, while 15% is found in soft tissue. The remaining phosphate 
(<1%) circulates in the extracellular fluid [29].
Similar to calcium homeostasis, phosphate balance relies on a complex relationship between 
the intestine, kidneys, bone, as well as regulatory hormones including PTH, FGF23 and klotho.
3.2. Dietary phosphorus
Humans consume between 700 and 2000 mg of dietary phosphorus each day. Phosphorus is 
present in dairy and protein-rich foods including meat and poultry. It is frequently added to 
salt and processed foods. With the increase in consumption of processed foods, average dietary 
intake has increased [30]. In the human body, phosphorus is present in the form of phosphate [1].
3.3. Physiology of phosphate
The majority, 85%, of phosphate in the body exists as bone. The remaining balance of phos-
phate is present as free anions or forms organophosphate compounds. Organophosphate 
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compounds act as structural proteins, enzymes, transcriptional factors, nucleic acids, energy 
(adenosine triphosphate, creatine phosphate), carbohydrates and lipids [4].
Normal serum phosphate levels in adults range between 0.75 and 1.45 mmol/L (2.5–4.5 mg/dL). 
Serum phosphate levels do not always reflect available phosphate levels given that phosphate 
moves freely between the extracellular and intracellular compartments [4].
3.3.1. Renal handling of phosphate
Regulation of renal phosphate reabsorption is felt to be the most critical mechanism in phos-
phate homeostasis [8, 29]. Each day, 4–6 g of phosphate is filtered by glomeruli.
Eighty-five percent of phosphate undergoes reabsorption at the PCT. This occurs via the type 
II sodium-phosphate cotransporters Npt2a (SLC34A1) and Npt2c (SLC34A3) located on the 
brush border of the apical membrane [28, 31]. These cotransporters are endocytosed, favouring 
phosphaturia, in the presence of PTH, high dietary phosphorus or FGF23. They have a rapid 
response to changes in the PTH level, with the number of cotransporters adjusting within min-
utes. It takes approximately 2 hours for the number of cotransporters to change based on dietary 
phosphorus intake [28]. Npt2c is thought to have less of an influence on phosphate homeostasis 
in mice as Npt2a knockout mice continue to have profound phosphaturia despite the presence 
of Npt2c. However, this cotransporter may play a more significant role in human phosphate 
homeostasis [28]. In humans, mutations in Npt2c lead to hereditary hypophosphataemic rickets 
with hypercalciuria (HHRH) compared with mutations in Npt2a, which are characterised by 
the development of nephrocalcinosis and increased osteoporotic risk. These findings support 
the importance of the Npt2c cotransporter in human phosphate balance [28, 32, 33].
The type III sodium-phosphate cotransporter, PiT2, has been located in the kidney, also at the 
brush border membrane. This transporter is upregulated by low dietary phosphate, albeit more 
slowly than the type II sodium-phosphate cotransporters, with changes in concentrations tak-
ing 8 hours [28].
Npt2a and 2c are responsible for transporting divalent phosphate with Npt2a, moving three 
sodium ions and one phosphate ion across the apical membrane creating an electrogenic 
gradient. Npt2c transports two sodium and one phosphate ion, resulting in electroneutral-
ity. PiT2 carries monovalent phosphate, also developing an electrogradient [1]. An unknown 
transporter on the basolateral membrane is thought to be responsible for phosphate transport 
to peritubular capillaries. This is represented in Figure 4.
Hypocalcaemia, hypomagnesaemia, hypophosphataemia and dehydration inhibit reabsorp-
tion of phosphate at the kidney. Fluid overload upregulates phosphate excretion [4].
3.3.2. Intestinal handling of phosphate
Different species display diverse mechanisms for intestinal absorption of phosphate, and 
therefore the understanding of human intestinal phosphate handling is incomplete [34].
Intestinal phosphate absorption occurs via passive paracellular and active transcellular trans-
port. In healthy humans, 60–75% of dietary phosphorus is absorbed [4, 21]. Paracellular trans-
port involves passive diffusion of phosphate through tight junctions and occurs independently 
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of any regulatory hormones [34]. The type II sodium-phosphate cotransporter, Npt2b 
(SLC34A2), and type III cotransporters, PiT1 and PiT2, modulate transcellular transport in the 
intestine. Npt2b is located on the apical membrane of enterocytes and is thought to be most 
abundant in the duodenum and jejunum in humans [1] although it is also found on lung, 
mammary, liver, and testis tissue [31, 34]. Mutations in Npt2b transporters do not manifest 
in clinically significant hypophosphataemia in humans, and this is thought to be due to renal 
compensation [28]. The type III cotransporters are predominately present on the basolateral 
intestinal membrane but can be found on the apical membrane [35].
Gastrointestinal absorption of phosphate is primarily upregulated by calcitriol and low 
dietary phosphate. FGF23 reduces the abundance and activity of sodium-phosphate 
cotransporters and will be discussed further in this chapter. Matrix extracellular phospho-
glycoprotein (MEPE) produced by osteoblasts and osteocytes inhibits renal and intestinal 
phosphate absorption independent of PTH and FGF23 [34]. Other regulators of phosphate 
absorption are glucocorticoids, oestrogen and the presence of metabolic acidosis [28]. 
Calcium salts, sevelamer hydrochloride and aluminium hydroxide prevent intestinal 
absorption of phosphate and are therefore used as phosphate binders in patients with 
chronic kidney disease [4].
3.3.3. Bone handling of phosphate
Similar to calcium, bone acts as a reservoir of phosphate. Phosphate can be resorbed from 
bone into the extracellular space to maintain serum levels of phosphate.
Figure 4. Sodium-phosphate cotransporters at the proximal convoluted tubule. Npt2a, Npt2c and PiT2 are located on 
the brush border of the apical membrane. Npt2a and 2c transport divalent phosphate. Npt2a transports three sodium 
ions with one phosphate ion, creating an electrogenic gradient. Npt2c moves two sodium ions for one phosphate, 
which is electroneutral. PiT2 carries monovalent phosphate creating an electrogradient. An unknown transporter on the 
basolateral membrane transports phosphate to peritubular capillaries [1].
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3.3.4. Fibroblast growth factor 23, klotho and phosphate homeostasis
FGF23 is the most widely studied phosphatonin and acts with its coreceptor, klotho. Dietary 
phosphorus and calcitriol increase the secretion of FGF23, which encourages phosphaturia 
through reduced Npt2a expression in the PCT. It plays a similar role in downregulating Npt2c 
and PiT2; however, in mice studies, this effect has been less pronounced [36]. Conversely, low 
dietary phosphorus inhibits FGF23 secretion.
FGF23 also contributes to phosphate homeostasis by regulating the number of intestinal 
sodium-phosphate cotransporters [1]. Similar to the kidney, cotransporters are less abundant 
in the presence of high levels of FGF23, preventing absorption of phosphorus.
Animal and in vitro studies have proved that FGF23 works directly on the parathyroid gland 
to decrease PTH production and release [37]. In chronic kidney disease, the parathyroid 
becomes increasingly resistant to the action of FGF23, contributing to the development of 
secondary and tertiary hyperparathyroidism [1]. As previously stated, FGF23 also inhibits 
calcitriol, preventing intestinal phosphate absorption and renal reabsorption [19].
3.3.5. PTH and phosphate homeostasis
PTH reduces the number of sodium-phosphate cotransporters, specifically Npt2a, in the 
kidney favouring phosphaturia [32, 37]. Serum phosphate levels have a direct effect on the 
parathyroid gland independent of calcitriol, calcium levels or FGF23. This is mediated by 
modulation of PTH gene expression and parathyroid cell proliferation [37] but requires intact 
and functioning parathyroid tissue [38].
3.4. Hyperphosphataemia
Hyperphosphataemia is most often associated with impairment in the kidney’s ability to excrete 
appropriate levels of phosphate [37]. Acute kidney injury leads to hyperphosphataemia due to 
a reduction in glomerular filtration rate [21]. In early chronic kidney disease, increased phos-
phate levels are compensated for by FGF23 initially, followed by PTH. With time and a further 
decrease in glomerular filtration (specifically, at less than an eGFR of 35 mL/min/1.732), these 
mechanisms are unable to accommodate due to loss of renal mass meaning that phosphate 
levels rise. Impaired calcitriol synthesis and bone mineralisation also contribute to elevated 
phosphate levels. Hyperphosphataemia drives secondary hyperparathyroidism and increased 
FGF23, which is common in patients with end-stage kidney disease [29]. FGF23 suppresses 
calcitriol with resultant adverse effects on cardiovascular and kidney health.
Other causes for hyperphosphataemia are driven by elevated exogenous phosphate, as 
seen following administration of phosphate enemas or excess endogenous phosphate. 
Bisphosphonate treatment can cause elevated phosphate levels due to the liberation of phos-
phate from bone. Rapid release of intracellular phosphate into the extracellular space is seen in 
rhabdomyolysis, tumour lysis syndrome and acidosis [29, 39]. As PTH has a significant influ-
ence on promoting phosphaturia, loss of PTH caused by hypoparathyroidism or peripheral 
resistance to its action (pseudohypoparathyroidism) can produce elevated phosphate levels 
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[21]. Familial tumoral calcinosis, an autosomal recessive disease caused by a mutation in the 
GALNT3, FGF23 or klotho gene, is characterised by resistance to FGF23, which also leads to 
hyperphosphataemia [40]. Increased levels of growth hormone and insulin-like growth factor 
1 (Igf-1) seen in acromegaly stimulate phosphate reabsorption in the PCT.
3.4.1. Clinical manifestations of hyperphosphataemia
Acute hyperphosphataemia results in soft tissue calcium and phosphate deposition contribut-
ing to hypocalcaemia. These individuals may present with manifestations of hypocalcaemia 
or with consequences of calcium phosphate deposition including nephrocalcinosis or heart 
block [4]. Chronic elevation in phosphate levels can lead to vascular calcification, mineral 
bone disease, secondary hyperparathyroidism and calciphylaxis.
Elevated phosphate levels in patients requiring haemodialysis for end-stage kidney disease is 
associated with an increased risk of cardiovascular morbidity and mortality [41, 42].
Elevated FGF23 levels, seen in individuals with hyperphosphataemia, have been found to con-
tribute to left ventricular hypertrophy, reduced erythropoiesis and increased inflammation [36].
3.4.2. Treatment of hyperphosphataemia
Acute hyperphosphataemia is managed with intravenous fluids, renal replacement therapy 
and treatment of the underlying cause [21].
Management of hyperphosphataemia remains a challenge in patients with chronic kidney 
disease. Low phosphate diets, phosphate binders and dialysis are all used as treatment strate-
gies to maintain healthy phosphate levels. Intensive dialysis (daily or nocturnal dialysis) has 
been shown to decrease the requirement for phosphate binders and dietary restriction [43].
3.5. Hypophosphataemia
Hypophosphataemia can be caused by impaired phosphate absorption, increased phosphate 
loss or movement of phosphate from the extracellular space. Reduced phosphate consump-
tion is rare but seen in individuals who are not eating and in those who abuse alcohol. 
Hypophosphataemia is a known consequence of refeeding syndrome. Primary hyperpara-
thyroidism often presents with mild hypercalcaemia and hypophosphataemia.
Inherited disorders including autosomal dominant, autosomal recessive or X-linked hypo-
phosphataemic rickets and vitamin D-dependent rickets cause excess phosphate loss associ-
ated with skeletal deformities. Primary hyperparathyroidism encourages downregulation of 
NPT2a, resulting in phosphaturia. Proximal tubular dysfunction occurs in proximal tubu-
lar acidosis or Fanconi syndrome and contributes to phosphate loss. Hypophosphataemia 
is common following renal transplantation and is thought to be secondary to persistently 
elevated FGF23 levels [21].
Causes of intracellular redistribution of phosphate include diabetic ketoacidosis, acute respi-
ratory alkalosis, likely due to muscular sequestration of extracellular phosphate (chronic 
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respiratory alkalosis leads to hyperphosphataemia) and insulin therapy. If phosphate is omit-
ted from TPN, it can cause reductions in serum phosphate. Rarely, mesenchymal tumours 
such as haemangiopericytomas, fibromas and angiosarcomas can secrete phosphatonins such 
as FGF23. Subsequently, this results in phosphaturia and hypophosphataemia.
3.5.1. Clinical manifestations of hypophosphataemia
Hypophosphataemia does not cause clinical sequela until levels are less than 0.65 mmol/L 
(2 mg/dL). Muscle weakness, including diaphragmatic weakness and reduced cardiac contrac-
tility, can be a consequence of hypophosphataemia. Other manifestations include osteoma-
lacia, metabolic encephalopathy, haemolysis, leukocyte dysfunction and thrombocytopaenia 
[4, 21, 42].
3.5.2. Treatment of hypophosphataemia
Dairy intake or oral phosphate supplementation can treat hypophosphataemia, except in 
cases of nephrocalcinosis or nephrolithiasis due to urinary phosphate wasting. In the case of 
severe hypophosphataemia, intravenous replacement should be given. In individuals requir-
ing parenteral nutrition, phosphate needs to be added to any nutritional supplement.
4. Magnesium
4.1. The importance of magnesium
The divalent cation magnesium plays an integral role in neuromuscular activity. On an 
intracellular level, it is the second most abundant cation [21]. It is essential to the activation 
of adenosine triphosphate (ATP), intracellular signalling, glycolysis, protein formation, cell 
growth as well as DNA production and transcription [44]. Given its function at the cellular 
level, it is essential in the role of many human organs including the heart, vasculature, muscle, 
bone and central and peripheral nervous systems [44].
The normal plasma level of magnesium is 0.7–1.1 mmol/L (1.7–2.6 mg/dL). Similar to calcium and 
phosphate homeostasis, the kidney, intestine and bone are essential in maintaining its balance.
4.2. Dietary magnesium
The average daily consumption of magnesium from the diet is 140–360 mg. Many foods 
including fruits, vegetables, cereals, grains, nuts and legumes contain magnesium [45]. 
Processed, refined and boiled foods are low in magnesium as are dairy products [44, 45].
4.3. Physiology of magnesium
Around 20–28 g of magnesium is present in an average-sized adult with more than half of 
this being stored in bone [4, 45]. The remaining magnesium is distributed in muscle and soft 
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tissue, and 1% is found in the extracellular compartment [1, 4, 44]. About 30% of magnesium 
is bound to protein, including albumin, with 10% bound to ATP, nucleic acids, and phospho-
lipids [1]. The remaining 60% exists in the ionised state; it is physiologically active in this form.
Many essential functions in the human body require magnesium; however, it does not appear 
that hormones have a significant influence on its balance. The kidney, intestine and bone are 
primarily responsible for maintaining healthy magnesium levels.
4.3.1. Renal handling of magnesium
Under normal physiological conditions, 2000–2400 mg of magnesium is filtered by the kidney 
each day. Around 10–20% of filtered magnesium undergoes reabsorption by the PCT. This 
occurs through a predominately paracellular pathway driven by a transepithelial electro-
chemical gradient caused by sodium reabsorption [46]. In the TALH, 50–70% of magnesium is 
reabsorbed, also via a paracellular pathway. A lumen-positive transepithelial gradient driven 
by NKCC2 and ROMK is required. Loop diuretics inhibit the NKCC2 transporter, result-
ing in magnesium excretion. Claudin-16 and claudin-19 affect the tight junction permeability 
at the TALH, also altering magnesium reabsorption [46]. The DCT reabsorbs the remaining 
10–15% of magnesium. Here, reabsorption occurs through a transcellular pathway mediated 
by TRPM6, which is present on the apical surface [46, 47]. Epidermal growth factor (EGF) [48] 
and the sodium-potassium-ATPase transporter increase TRPM6 and therefore the transport 
of magnesium. The magnesium-sodium exchanger (SLC41A1) on the basolateral membrane 
facilitates reabsorption into the peritubular capillaries [49].
Renal magnesium reabsorption is thought to be upregulated by PTH but inhibited by hyper-
magnesaemia and hypercalcaemia [4].
4.3.2. Gastrointestinal handling of magnesium
Intestinal absorption of magnesium depends on dietary intake, but approximately 40% is 
absorbed. In humans, this predominately takes place in the jejunum and ileum with a small 
amount being reabsorbed in the colon [44, 50].
Saturable, transcellular magnesium absorption occurs through TRMP6 and TRMP7 channels 
[1, 44, 47]. Thirty percent of intestinal magnesium absorption occurs through the transcel-
lular mechanism; however, this increases in the instance of low dietary magnesium intake. In 
cases of high luminal magnesium, the paracellular route predominately drives transport and 
accounts for 80–90% of intestinal magnesium uptake.
4.3.3. Bone handling of magnesium
Around 50–60% of bodily magnesium is stored in the bone as hydroxyapatite crystals [46]. 
Half of this is insoluble with the remainder being freely exchangeable with the extracellular 
fluid. Magnesium has been found to encourage osteoblast differentiation and proliferation, 
resulting in reduced bone formation in hypomagnesaemic individuals [51].
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4.4. Hypermagnesaemia
Exogenous magnesium is found in oral and intravenous magnesium supplementation, rectal 
enemas, antacids, laxatives and urethral irrigation solutions [45]. Elevated magnesium levels 
are seen in patients given exogenous magnesium in the context of renal insufficiency but can 
occur in the presence of normal renal function [21, 45]. The release of intracellular magne-
sium into the extracellular space is seen in individuals with severe burns, trauma or shock. 
Associations with hypermagnesaemia include familial hypocalciuric hypercalcaemia, adrenal 
insufficiency, hypothyroidism and hypothermia.
4.4.1. Clinical manifestations of hypermagnesaemia
Clinical sequelae caused by hypermagnesaemia can occur with levels greater than 2 mmol/L 
(4.8 mg/dL). Hypermagnesaemia can cause hypotension as a result of vasodilation. Other man-
ifestations include nausea, vomiting, fatigue, neurological impairment and potentially paraly-
sis. Deep tendon reflexes are lost when serum magnesium is greater than 3 mmol/L. Reduced 
bowel sounds, facial flushing, dilated pupils and heart block are clinical signs, which may 
manifest [1, 4].
4.4.2. Treatment of hypermagnesaemia
Hypermagnesaemia requires management by ceasing exogenous magnesium administra-
tion. Intravenous hydration and intravenous calcium can be used in symptomatic individuals. 
Calcium is thought to antagonise the effects of magnesium at the neuromuscular junction. Renal 
replacement therapy is an option in those with chronic kidney disease.
4.5. Hypomagnesaemia
Gastrointestinal causes for hypomagnesaemia include inadequate dietary magnesium intact, 
gastrointestinal loss through vomiting or diarrhoea, malabsorption, small bowel surgery and 
alcoholism [46, 52]. Primary familial hypomagnesaemia caused by TRPM6 mutations can 
result in reduced gastrointestinal absorption and renal loss.
Excessive renal magnesium loss at the PCT is seen with the use of frusemide and in Bartter syn-
drome; although this is usually mild due to distal compensation. Hypercalcaemia leads to hypo-
magnesaemia due to competition for transport at the TALH and CaSR activation [52]. Familial 
hypomagnesaemia with hypercalciuria can occur in mutations of claudin-16 and 19 [53]. At the 
DCT, thiazide diuretics and Gitelman syndrome cause urinary magnesium loss. EGF upregu-
lates TRPM6, and therefore EGF receptor inhibitors (cetuximab, panitumumab) contribute to 
hypomagnesaemia. Nephrotoxic medication such as aminoglycosides, amphotericin B, cisplatin, 
calcineurin inhibitors, pentamidine and cyclosporine can cause hypomagnesaemia [4].
In refeeding syndrome, recovery from diabetic ketoacidosis, pancreatitis, bony metastatic 
disease and post-parathyroidectomy magnesium can shift from the extracellular to intracel-
lular space.
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Chronic proton pump inhibitor use has been associated with hypomagnesaemia, particularly 
with concomitant diuretic use [52, 54]. The mechanism behind this has been thought to be due 
to reduced gastrointestinal absorption although causality remains under investigation [54].
4.5.1. Clinical manifestations of hypomagnesaemia
Hypomagnesaemia can result in mood changes, fatigue, muscular spasm, weakness and neu-
romuscular excitability, which may manifest as hyperreflexia, carpopedal spasm, seizures 
and tremor [46]. Prolonged QT intervals and ST depression resulting in cardiac arrhythmias 
can occur. Hypomagnesaemia may potentiate digoxin toxicity. Due to urinary losses, hypo-
calcaemia and hypokalaemia are often seen with hypomagnesaemia [21].
4.5.2. Treatment of hypomagnesaemia
Hypomagnesaemia requires treatment with oral or intravenous replacement. Oral magne-
sium supplementation is not well absorbed when used in high doses and can cause diarrhoea. 
Individuals presenting with symptoms or cardiac manifestations should be treated promptly 
with intravenous magnesium [45].
5. Conclusion
Calcium, phosphate and magnesium are electrolytes found in the human body, which rely 
on tight regulatory control in order to support human life and function. The kidney, intestine 
and bone are essential in maintaining the fine balance. Diseases affecting any of these organs, 
or the hormones involved in homeostasis, can disrupt the levels of each electrolyte causing 
symptomatic and potentially life-threatening consequences.
In addition to the kidney, intestine and bone, calcium relies on PTH, PTHrP, phosphate, 
cholecalciferol, calcitriol, FGF23 and klotho to maintain normal serum levels in the human 
body. Individuals with hypercalcaemia and hypocalcaemia can present with asymptomatic 
or symptomatic disease depending on the severity and chronicity. It is important to manage 
each condition to prevent immediate and long-term complications.
Phosphate and calcium and dependent on each other with disruption to the balance of one 
having impacts on the other. Phosphate homeostasis is also reliant on PTH, FGF23 and klotho. 
Hyperphosphataemia is common in patients with chronic kidney disease and has many long-
term ramifications, and hypophosphataemia can lead to severe illness and death.
Magnesium does not appear to rely on hormonal control. It plays important roles in neuro-
muscular activity. Hypermagnesaemia is rare in cases of normal renal function and is most 
often a result of exogenous ingestion. Hypomagnesaemia may be due to a wide array of 
causes and disturbs neuromuscular signalling.
Clinicians require a thorough understanding of the intricacies of calcium, phosphate and mag-
nesium homeostasis in order to prevent, diagnose and manage complications of disturbance.
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